TNF and autoimmune hepatitis: Case series and a pharmacovigilance database study have reported autoimmune hepatitis and other hepatobiliary events with anti-TNFα agents (14, 15); a systematic review has also summarized biologic-related liver injury across agents (13), but head-to-head comparisons among TNF inhibitors remain scarce.